Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac mesotherapy versus methylprednisolone trigger point injection for lumbosacral canal stenosis
IRCT20250530065985N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in lumbar spinal stenosis (LSS) comparing Methylprednisolone trigger point injection with Ketorolac mesotherapy (2 arms). Primary endpoints: Pain reduction and Functional improvement. Started Sep 2025; status: completed.
02
Drugs
ketorolacmethylprednisolone
03
Conditions
lumbar spinal stenosis (LSS)
Beyond the preview
Go deeper on IRCT20250530065985N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250530065985N1.